Literature DB >> 4894302

Complement metabolism in man: hypercatabolism of the fourth (C4) and third (C3) components in patients with renal allograft rejection and hereditary, angioedema (HAE).

C B Carpenter, S Ruddy, I H Shehadeh, H J Müller-Eberhard, J P Merrill, K F Austen.   

Abstract

Highly purified and radioiodinated human C4 and (or) C3 were administered to patients with renal allografts in rejection, with hereditary angioedema (HAE), with chronic glomerulonephritis, and to control subjects. The latter group included normal individuals, anephric patients before transplantation, and stable renal allograft recipients. The catabolic rates of these complement proteins were determined by analysis of the disappearance of plasma protein-bound radioactivity (k(m)), and by direct measurement of urinary excretion of radioactivity (k(u)). The correlation coefficient between these two methods was 0.96. The mean +/-2 SD for catabolic rates in the control subjects was 0.9-2.7% plasma pool/hr for C4 and 0.9-2.0% plasma pool/hr for C3. Patients experiencing renal allograft rejection had unstable levels of C4 and C3, and exhibited moderate hypercatabolism of both proteins. One patient with chronic glomerulonephritis had hypercatabolism of C4 and C3 in the presence of stable normal serum levels. In patients with HAE who had extremely low levels of C4, catabolic rates for C4 were markedly elevated (3.7, 5.8, 7.0 and 8.8%/hr). Analysis of plasma curves in HAE revealed a three component disappearance curve instead of the two component curve in control subjects receiving the same preparation. Even though C3 levels were normal, moderate hypercatabolism of C3 was also present in HAE (2.6, 2.8, 2.8, and 3.2% of pool/hr). The marked hypercatabolism of C4 in HAE constitutes the first direct evidence for the in vivo destruction by uninhibited C1 esterase of its natural substrate C4. The moderate hypercatabolism of C3 is consistent with the in vivo formation of C3-convertase.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4894302      PMCID: PMC322377          DOI: 10.1172/JCI106116

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE.

Authors:  V H DONALDSON; F S ROSEN
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

2.  Studies of I-131-albumin catabolism and distribution in normal young male adults.

Authors:  W L BEEKEN; W VOLWILER; P D GOLDSWORTHY; L E GARBY; W E REYNOLDS; R STOGSDILL; R S STEMLER
Journal:  J Clin Invest       Date:  1962-06       Impact factor: 14.808

3.  Effects of plasmapheresis on albumin pools in rabbits.

Authors:  C M MATTHEWS
Journal:  J Clin Invest       Date:  1961-03       Impact factor: 14.808

4.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

5.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

6.  Intravascular coagulation (IVC) in human renal allograft rejection.

Authors:  G J Busch; W E Braun; C B Carpenter; J M Corson; E R Galvanek; E S Reynolds; J P Merrill; G J Dammin
Journal:  Transplant Proc       Date:  1969-03       Impact factor: 1.066

7.  In vivo metabolism of complement. I. Metabolism of the third component (C'3) in acquired hemolytic anemia.

Authors:  L D Petz; D J Fink; E A Letsky; H H Fudenberg; J Müller-Eberhard
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

8.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT.

Authors:  H J MUELLER-EBERHARD; C E BIRO
Journal:  J Exp Med       Date:  1963-09-01       Impact factor: 14.307

View more
  17 in total

1.  A quantitative lateral flow assay to detect complement activation in blood.

Authors:  Elizabeth C Schramm; Nick R Staten; Zhouning Zhang; Samuel S Bruce; Christopher Kellner; John P Atkinson; Vasileios C Kyttaris; George C Tsokos; Michelle Petri; E Sander Connolly; Paul K Olson
Journal:  Anal Biochem       Date:  2015-02-04       Impact factor: 3.365

2.  The complement system in renal homograft recipents.

Authors:  T Yokoyama; M Torisu; A L Durst; G Schroter; C G Groth; T E Starzl
Journal:  Surgery       Date:  1972-10       Impact factor: 3.982

3.  The nature of experimental second-set kidney transplant rejection. 3. The role of complement.

Authors:  W J Dempster; D L Brown
Journal:  Br J Exp Pathol       Date:  1971-06

4.  Hereditary angioedema. A report of three families.

Authors:  F Kueppers; K H Schulz
Journal:  Humangenetik       Date:  1972

5.  Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus.

Authors:  A J Sliwinski; N J Zvaifler
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

Review 6.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

7.  C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.

Authors:  J H Wild; N J Zvaifler; H J Müller-Eberhard; C B Wilson
Journal:  Clin Exp Immunol       Date:  1976-05       Impact factor: 4.330

8.  In vitro activation of C1s in plasma of patients with hereditary angioneurotic oedema.

Authors:  S Shafiasghar; R H Cormane; K W Pondman
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

9.  Activation of the alternative complement pathway in systemic lupus erythematosus.

Authors:  M R Wilson; C M Arroyave; R M Nakamura; J H Vaughan; E M Tan
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

Review 10.  Angioedema. Pathogenesis, differential diagnosis, and treatment.

Authors:  Evangelo Frigas; Ugochukwu C Nzeako
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.